Proliferative Diabetic Retinopathy

Ophthalmology
5
Pipeline Programs
4
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
150%
Monoclonal Antibody
150%
+ 4 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Genentech
GenentechCA - Oceanside
2 programs
2
Prompt Panretinal PhotocoagulationPhase 31 trial
RanibizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT01489189Completed305Est. Feb 2018
NCT00445003Completed333Est. Jul 2010
Novartis
NovartisBASEL, Switzerland
1 program
1
Octreotide, 30 mg i.m. LAR formulationPhase 3Peptide1 trial
Active Trials
NCT00170742Terminated17
Regeneron
RegeneronTARRYTOWN, NY
2 programs
2
2-mg Intravitreous Aflibercept InjectionPhase 2/31 trial
Intravitreal Aflibercept InjectionPhase 2/31 trial
Active Trials
NCT02858076Completed205Est. Jan 2020
NCT01813773Completed20Est. Apr 2016
Pfizer
PfizerNEW YORK, NY
1 program
MacugenN/A3 trials
Active Trials
NCT00549055Completed38Est. Oct 2009
NCT00446381Completed28Est. Sep 2008
NCT01245387Completed1,001Est. Dec 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GenentechPrompt Panretinal Photocoagulation
GenentechRanibizumab
NovartisOctreotide, 30 mg i.m. LAR formulation
Regeneron2-mg Intravitreous Aflibercept Injection
RegeneronIntravitreal Aflibercept Injection
PfizerMacugen
PfizerMacugen
PfizerMacugen

Clinical Trials (8)

Total enrollment: 1,947 patients across 8 trials

NCT01489189GenentechPrompt Panretinal Photocoagulation

Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Start: Mar 2012Est. completion: Feb 2018305 patients
Phase 3Completed
NCT00445003GenentechRanibizumab

Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy

Start: Mar 2007Est. completion: Jul 2010333 patients
Phase 3Completed
NCT00170742NovartisOctreotide, 30 mg i.m. LAR formulation

Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.

Start: Dec 200317 patients
Phase 3Terminated
NCT02858076Regeneron2-mg Intravitreous Aflibercept Injection

Anti-VEGF vs. Prompt Vitrectomy for VH From PDR

Start: Nov 2016Est. completion: Jan 2020205 patients
Phase 2/3Completed
NCT01813773RegeneronIntravitreal Aflibercept Injection

Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study

Start: Mar 2013Est. completion: Apr 201620 patients
Phase 2/3Completed
NCT00549055PfizerMacugen

A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.

Start: Nov 2007Est. completion: Oct 200938 patients
N/ACompleted
NCT00446381PfizerMacugen

Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)

Start: Oct 2006Est. completion: Sep 200828 patients
N/ACompleted
NCT01245387PfizerMacugen

Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration

Start: Aug 2006Est. completion: Dec 20091,001 patients
N/ACompleted

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
4h ago

Cleanroom and Laboratory Technician

SAB BIO
4h ago

Product Specialist

Johnson & Johnson
Hangzhou, Zhejiang, China
20h ago

BM 喀什 PSR HY

Johnson & Johnson
Urumqi, Xinjiang, China
20h ago

Site Delivery Leader MLL

Johnson & Johnson
Gent, East Flanders, Belgium
20h ago

Clinical Operations Manager

Johnson & Johnson
Irvine, California, United States of America
20h ago
$117K - $201K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Dry Eye(74)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)